Luvometinib

DB21696InvestigationalSmall molecule

Luvometinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Luvometinib is a tyrosine kinase inhibitor. Luvometinib is under investigation in clinical... Luvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Dual specificity mitogen-activated protein kinase kinase 2
Curator reviewed
Formula / weight: C₂₆H₂₂F₂IN₅O₄S · 665.45 g/mol (avg)
Code names: FCN-159

Resolves to

Compound

UNIIB2DYT4V89XCAS2739690-43-6ChEMBLCHEMBL6068059ChEBI759977PubChem135210935

Structure

InChIKeyRJFDJJABNSVLRB-UHFFFAOYSA-NSMILESCN1C(=O)C(F)=C(NC2=CC=C(I)C=C2F)C2=C1C(=NN(C1CC1)C2=O)C1=CC(NS(=O)(=O)C2CC2)=CC=C1

Targets

Q02750MAP2K1P36507MAP2K2

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Luvometinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account